Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media (lawsuits, restructuring, misconduct or financial distress) involving Radiometer found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving Radiometer found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Aug 2026: Radiometer began an FDA Class 2 correction of ABL90 FLEX/FLEX PLUS blood gas analysers (software 3.6 and lower) over potentially inaccurate results, updating instructions for use. In Mar 2025 a separate Class 2 recall addressed analysers freezing mid-measurement.
Contract delivery, go-lives, terminations and disputes.
No contract disputes, terminations or notable NHS/UK contract events involving Radiometer found in HSH's search of the last 24 months.